Skip to main content

Advertisement

SpringerLink
Log in

The Landmark Series: Axillary Management in Breast Cancer

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

The evolution in axillary management for patients with breast cancer has resulted in multiple dramatic changes over the past several decades. The end result has been an overall deescalation of surgery in the axilla. Landmark trials that have formed the basis for the current treatment guidelines are reviewed herein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fisher B et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312(11):674–81.

    Article  CAS  Google Scholar 

  2. Fisher B et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–75.

    Article  Google Scholar 

  3. Giuliano AE et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.

    Article  CAS  Google Scholar 

  4. Krag DN et al. Sentinel lymph node resection compared with conventional axillary lymph node dissection in clinically node negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33.

    Article  Google Scholar 

  5. Mansel RE et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98(9):599–609.

    Article  Google Scholar 

  6. Giuliano AE et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32.

    PubMed  PubMed Central  Google Scholar 

  7. Giuliano AE et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg. 2016;264(3):413–20.

    Article  Google Scholar 

  8. Giuliano AE et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918–26.

    Article  Google Scholar 

  9. Lucci A et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657–63.

    Article  Google Scholar 

  10. Guiliano AE et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306(4):386–93.

    Google Scholar 

  11. Galimberti V et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305.

    Article  Google Scholar 

  12. Sola M et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013;20(1):120–7.

    Article  Google Scholar 

  13. Donker M et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.

    Article  Google Scholar 

  14. Voogd AC et al. The risk of nodal metastases in breast cancer patients with clinically negative lymph nodes: a population-based analysis. Breast Cancer Res Treat. 2000;62:63–9.

    Article  CAS  Google Scholar 

  15. Lanng C et al. Assessment of clinical palpation of the axilla as a criterion for performing the sentinel node procedure in breast cancer. EJSO. 2006;33:281–4.

    Article  Google Scholar 

  16. Specht MC et al. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy? J Am Coll Surg. 2005;200:10–4.

    Article  Google Scholar 

  17. Mamounas EP et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23:2694–702.

    Article  Google Scholar 

  18. Hennessy BT et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23(36):9304–11.

    Article  Google Scholar 

  19. Boughey JC et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260(4):608–16.

    Article  Google Scholar 

  20. Boughey JC et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.

    Article  CAS  Google Scholar 

  21. Boughey JC et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015;33(30):3386–93.

    Article  CAS  Google Scholar 

  22. Boughey JC et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802–7.

    Article  Google Scholar 

  23. Kuehn T et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicenter cohort study. Lancet Oncol. 2013;14:609–18.

    Article  Google Scholar 

  24. Boileau JF et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2014;33:258–64.

    Article  Google Scholar 

  25. NCT01901094: Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy. https://clinicaltrials.gov/ct2/show/NCT01901094. Accessed 27 Sept 2019.

  26. NCT01872975: Standard or comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery. https://clinicaltrials.gov/ct2/show/NCT01872975. Accessed 27 Sept 2019.

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA

    Carla S. Fisher MD

  2. Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA

    Julie A. Margenthaler MD

  3. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Kelly K. Hunt MD

  4. Department of Surgery, St. Louis University, St. Louis, MO, USA

    Theresa Schwartz MD

Authors
  1. Carla S. Fisher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julie A. Margenthaler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kelly K. Hunt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Theresa Schwartz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie A. Margenthaler MD.

Ethics declarations

Disclosure

Carla S. Fisher, Julie A. Margenthaler, Theresa Schwartz has nothing to disclose. Kelly K. Hunt – Merck & Co. Medical Advisory Board, Armada Health Medical Advisory BoardResearch funding to institution—Endomag and Lumicell.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fisher, C.S., Margenthaler, J.A., Hunt, K.K. et al. The Landmark Series: Axillary Management in Breast Cancer. Ann Surg Oncol 27, 724–729 (2020). https://doi.org/10.1245/s10434-019-08154-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-08154-5

Search

Navigation